San Diego-based Anadys Pharmaceuticals, a biotechnology firm developing medicines for treating viral and bacterial infections, has raised $71.3M in an IPO on the NASDAQ. The firm offered 5,750,000 shares of its stock at $12.40 per share. The IPO was managed by Credit Suisse First Boston, SG Cowen & Co., Piper Jaffray, and Needham & Company. The firm is backed by Coastview Capital, HBM Partners, Lotus BioScience, and Venrock Associates.
Top NewsThursday, August 11, 2005
Anadys Pharmaceuticals Raises $71.3M in IPO